Clinical Trial Detail

NCT ID NCT03737643
Title Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients. (DUO-O)
Recruitment Recruiting
Gender female
Phase Phase III
Variant Requirements No
Sponsors AstraZeneca

fallopian tube cancer

peritoneum cancer

ovary serous adenocarcinoma

endometrioid ovary carcinoma

ovarian clear cell carcinoma

ovarian carcinosarcoma


Bevacizumab + Carboplatin + Paclitaxel

Bevacizumab + Carboplatin + Durvalumab + Paclitaxel

Bevacizumab + Durvalumab + Olaparib


Bevacizumab + Durvalumab

Age Groups: senior adult

No variant requirements are available.